Portage Biotech Inc
NASDAQ:PRTG
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.16
37.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRTG stock under the Base Case scenario is 3.84 USD. Compared to the current market price of 4.2 USD, Portage Biotech Inc is Overvalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Portage Biotech Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRTG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Portage Biotech Inc
Balance Sheet Decomposition
Portage Biotech Inc
Current Assets | 5.2m |
Cash & Short-Term Investments | 3.3m |
Receivables | 86k |
Other Current Assets | 1.8m |
Non-Current Assets | 41k |
PP&E | 27k |
Other Non-Current Assets | 14k |
Current Liabilities | 3m |
Accounts Payable | 1.5m |
Accrued Liabilities | 1.3m |
Other Current Liabilities | 211k |
Non-Current Liabilities | -279k |
Other Non-Current Liabilities | -279k |
Earnings Waterfall
Portage Biotech Inc
Revenue
|
0
USD
|
Operating Expenses
|
-98.8m
USD
|
Operating Income
|
-98.8m
USD
|
Other Expenses
|
27.7m
USD
|
Net Income
|
-71.1m
USD
|
Free Cash Flow Analysis
Portage Biotech Inc
USD | |
Free Cash Flow | USD |
PRTG Profitability Score
Profitability Due Diligence
Portage Biotech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Portage Biotech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PRTG Solvency Score
Solvency Due Diligence
Portage Biotech Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Portage Biotech Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTG Price Targets Summary
Portage Biotech Inc
Dividends
Current shareholder yield for PRTG is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. The company is headquartered in Toronto, Ontario and currently employs 6 full-time employees. The company went IPO on 2013-10-28. The firm is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Its portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.
Contact
IPO
Employees
Officers
The intrinsic value of one PRTG stock under the Base Case scenario is 3.84 USD.
Compared to the current market price of 4.2 USD, Portage Biotech Inc is Overvalued by 9%.